Implantica AG (STU:8IM1)

Q4 2025 Implantica AG Earnings Call Transcript

Feb 25, 2026 / 02:00 PM GMT

Release Date Price: €4.56 (+2.82%)

Transcript

Key Points

Positve

Implantica AG (OSTO:IMP A SDB) has achieved a significant milestone with over 1,500 procedures performed across 50 hospitals in Europe, showcasing the growing adoption of their RefluxStop device.
The company has built a strong clinical evidence base with 33 published or accepted manuscripts, supporting the efficacy and safety of their RefluxStop treatment.
Implantica AG is preparing for a US launch pending FDA approval, with plans to initially target 25 to 50 centers, leveraging existing reimbursement codes to facilitate market entry.
The company maintains exceptional gross margins, with an adjusted gross margin of 92% for the fourth quarter, indicating strong cost management and pricing strategy.
Implantica AG holds a solid financial position with €48.9 million in cash and short-term investments, providing a stable foundation for future growth and expansion.

Negative

The FDA approval process for RefluxStop has faced delays due to third-party testing issues, impacting the timeline for US market entry.
Operating losses for the fourth quarter increased by 3% year-on-year, highlighting ongoing financial challenges as the company invests in R&D and market expansion.
Reimbursement challenges in Europe continue to hinder widespread adoption, with full reimbursement not yet achieved in key markets like Germany and the UK.
The company's reliance on a modular PMA submission to the FDA means that any additional feedback or requirements could further delay approval and market entry.
Despite the potential market size, the European market remains complex and fragmented, requiring significant effort and time to achieve full market penetration and reimbursement.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IMPsdba.ST - Implantica AG
Q4 2025 Implantica AG Earnings Call
Feb 25, 2026 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
No questions.

Lighting.

I read out the.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Questions?

Welcome to the Implantica Q4 2025 report presentation. For the first part of the presentation, the participants will be in listen-only mode. During the questions and answer session, participants are able to ask questions by dialing pound 5 on their telephone keypad. Now I will hand the conference over to the speakers, CEO Peter Forscell, CFO Andreas Ornberg, and Chief Corporate Affairs Officer Nicole Pearson. Please go ahead.

-------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.